Remifentanil and Glycemic Response in Cardiac Surgery

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the effect of using remifentanil during cardiopulmonary bypass surgery to supress the hyperglycemic response in perioperative period. Half of the participants will receive continuous intravenous remifentanil during surgery, while the other half will receive intermittent intravenous fentanyl during surgery. Intermittent intravenous fentanyl administration is this institution's standard of care.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kathirvel Subramaniam; University of Pittsburgh
• Collaborator: Mylan Inc.
• Treatments: Fentanyl; Remifentanil

Criteria

Inclusion Criteria:

• Open cardiac surgery through sternotomy approach (coronary artery bypass, valve surgery, and any other open heart surgeries)

• Surgery with use of cardiopulmonary bypass

• Patients over 18 years of age

• Both female and male genders

• All races

Exclusion Criteria:

• Minimally invasive heart surgery through thoracotomy approach

• Patients receiving regional analgesia such as intrathecal morphine

• Patients undergoing procedures under deep hypothermic circulatory arrest

• Patients with active infections such as acute infective endocarditis

• Emergency surgery

• Patients undergoing transplantations and ventricular assist device insertion

• Patients on any mechanical circulatory support preoperatively

• Patient's refusal

• Allergy to remifentanil

• Positive pregnancy test

• Morbid obesity

• End stage liver and kidney disease